ZA961563B - Benzothiophene compounds, intermediates, compositions, and methods. - Google Patents
Benzothiophene compounds, intermediates, compositions, and methods.Info
- Publication number
- ZA961563B ZA961563B ZA9601563A ZA961563A ZA961563B ZA 961563 B ZA961563 B ZA 961563B ZA 9601563 A ZA9601563 A ZA 9601563A ZA 961563 A ZA961563 A ZA 961563A ZA 961563 B ZA961563 B ZA 961563B
- Authority
- ZA
- South Africa
- Prior art keywords
- intermediates
- compositions
- methods
- benzothiophene compounds
- benzothiophene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/396,401 US5510357A (en) | 1995-02-28 | 1995-02-28 | Benzothiophene compounds as anti-estrogenic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA961563B true ZA961563B (en) | 1997-09-17 |
Family
ID=23567054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9601563A ZA961563B (en) | 1995-02-28 | 1996-02-27 | Benzothiophene compounds, intermediates, compositions, and methods. |
Country Status (6)
Country | Link |
---|---|
US (6) | US5510357A (ru) |
AR (1) | AR027162A1 (ru) |
GE (1) | GEP20084496B (ru) |
HU (1) | HUP9600448A3 (ru) |
RU (1) | RU2158737C2 (ru) |
ZA (1) | ZA961563B (ru) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5824644A (en) * | 1994-07-07 | 1998-10-20 | G. D. Searle & Co. | Method of attenuating arterial stenosis |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5977093A (en) * | 1995-02-28 | 1999-11-02 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5998441A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5856339A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5856340A (en) | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
US5919800A (en) * | 1995-02-28 | 1999-07-06 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
US5998401A (en) | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5567828A (en) * | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
JPH11510479A (ja) | 1995-06-07 | 1999-09-14 | ネオルックス コーポレイション | タモキシフェン類似体による心臓血管疾病の予防及び治療 |
WO1997025033A1 (en) * | 1995-10-31 | 1997-07-17 | Eli Lilly And Company | Antithrombotic diamines |
US6432982B1 (en) | 1996-02-21 | 2002-08-13 | Eli Lilly And Company | Benzothiophenes, and formulations and methods using same |
BR9707657A (pt) * | 1996-02-22 | 1999-07-27 | Lilly Co Eli | Benzotiofenos formulações contendo os mesmos e métodos |
IL120266A (en) * | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
US5688796A (en) * | 1996-03-12 | 1997-11-18 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes, compositions, and methods |
ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
CA2214072C (en) * | 1996-08-29 | 2006-11-14 | Eli Lilly And Company | Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods |
CA2214919A1 (en) * | 1996-09-24 | 1998-03-24 | Kenneth Lee Hauser | Benzothiophene compounds, intermediates, processes, compositions, and methods |
US5958969A (en) * | 1996-10-10 | 1999-09-28 | Eli Lilly And Company | Benzo b!thiophene compounds, intermediates, formulations, and methods |
CA2216592C (en) * | 1996-10-24 | 2006-07-18 | Brian Stephen Muehl | Benzothiophene compounds, intermediates, compositions, and methods |
ZA982819B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
ZA982818B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Prevention of breast cancer using selective estrogen receptor modulators. |
AU7274098A (en) | 1997-04-30 | 1998-11-24 | Eli Lilly And Company | Antithrombotic agents |
ATE286395T1 (de) | 1997-04-30 | 2005-01-15 | Lilly Co Eli | Antithrombotische mittel |
AU7170898A (en) | 1997-04-30 | 1998-11-24 | Eli Lilly And Company | Antithrombotic agents |
JP2001522373A (ja) | 1997-04-30 | 2001-11-13 | イーライ・リリー・アンド・カンパニー | 抗血栓剤 |
EP0895989B1 (en) | 1997-08-07 | 2005-05-18 | Eli Lilly And Company | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity |
US5908859A (en) * | 1997-08-11 | 1999-06-01 | Eli Lilly And Company | Benzothiophenes for inhibiting hyperlipidemia |
WO1999018945A1 (en) * | 1997-10-14 | 1999-04-22 | Eli Lilly And Company | Method of building and maintaining bone |
US6096781A (en) * | 1997-11-14 | 2000-08-01 | Eli Lilly And Company | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome |
US6284756B1 (en) | 1998-04-30 | 2001-09-04 | Eli Lilly And Company | Antithrombotic agents |
CA2335295A1 (en) * | 1998-06-16 | 1999-12-23 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
JP2002518299A (ja) * | 1998-06-16 | 2002-06-25 | イーライ・リリー・アンド・カンパニー | アセチルコリンレベルを増加させる方法 |
US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
US6353003B1 (en) * | 1998-06-17 | 2002-03-05 | Eli Lilly And Company | Method for reducing levels of homocysteine and C-reactive protein |
US6087378A (en) * | 1998-10-13 | 2000-07-11 | Eli Lilly And Company | Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
EP0997460B1 (en) * | 1998-10-28 | 2002-12-11 | Eli Lilly And Company | Benzothiophene compounds as antithrombotic agents and intermediates |
ES2199605T3 (es) * | 1998-12-14 | 2004-02-16 | Vertex Pharmaceuticals (San Diego) Llc | Indicadores moleculares opticos de actividad del citocromo p450. |
US6420130B1 (en) * | 1998-12-14 | 2002-07-16 | Aurora Biosciences Corporation | Optical molecular sensors for cytochrome P450 activity |
EP1175433B1 (en) | 1999-05-04 | 2005-08-03 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
ES2208384T3 (es) * | 1999-07-29 | 2004-06-16 | Eli Lilly And Company | Forma cristalina de clorhidrato de 6 hidroxi-3-(4-(2-(piperidin-1-il)-etoxi)-fenoxi)2--(4-metoxifenil)-benzo(b)tiofeno. |
EP1204656A2 (en) * | 1999-07-29 | 2002-05-15 | Eli Lilly And Company | A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
US7122203B2 (en) * | 2000-05-08 | 2006-10-17 | Eli Lilly And Company | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof |
AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
WO2002018364A2 (en) * | 2000-08-25 | 2002-03-07 | Eli Lilly And Company | Process for preparing 2-phenyl-3-aminobenzothiophenes |
WO2002042289A2 (en) * | 2000-11-27 | 2002-05-30 | Eli Lilly And Company | Process for preparing 3-aryl-benzo[b]thiophenes |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
EP1401446B1 (en) * | 2001-05-22 | 2005-02-09 | Eli Lilly And Company | Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen |
US7056931B2 (en) * | 2001-05-22 | 2006-06-06 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
CN1599606A (zh) | 2001-07-31 | 2005-03-23 | 辉瑞产品公司 | 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法 |
US20040044224A1 (en) * | 2001-08-21 | 2004-03-04 | Conrad Preston Charles | Process for preparing 2-phenyl-3-aminobenzothiophenes |
BRPI0407690A (pt) | 2003-02-25 | 2006-03-01 | Lilly Co Eli | composto, e, métodos para tratar endometriose e para tratar leiomioma uterino |
MXPA06003122A (es) * | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos. |
CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
DE602005017577D1 (de) | 2004-01-22 | 2009-12-24 | Lilly Co Eli | Selektive östrogen-rezeptor-modulatoren |
EP1713770A1 (en) * | 2004-01-29 | 2006-10-25 | Eli Lilly And Company | Selective estrogen receptor modulators |
US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
PE20060167A1 (es) * | 2004-04-08 | 2006-04-20 | Wyeth Corp | Formulaciones de dispersion solida que comprende acetato de bazedoxifeno |
AU2005233128A1 (en) * | 2004-04-08 | 2005-10-27 | Wyeth | Bazedoxifene ascorbate as selective estrogen receptor modulator |
ES2558978T3 (es) | 2004-07-21 | 2016-02-09 | Mevion Medical Systems, Inc. | Generador de formas de ondas de radiofrecuencia programable para un sincrociclotrón |
EP1807079A1 (en) * | 2004-10-19 | 2007-07-18 | Eli Lilly And Company | Treatment of osteoarthritis and dosing regimen for arzoxifene |
AU2005308575A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
EP2389978B1 (en) * | 2005-11-18 | 2019-03-13 | Mevion Medical Systems, Inc. | Charged particle radiation therapy |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
US8933650B2 (en) * | 2007-11-30 | 2015-01-13 | Mevion Medical Systems, Inc. | Matching a resonant frequency of a resonant cavity to a frequency of an input voltage |
US8581523B2 (en) * | 2007-11-30 | 2013-11-12 | Mevion Medical Systems, Inc. | Interrupted particle source |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
US9161940B2 (en) | 2012-02-14 | 2015-10-20 | Repros Therapeutics Inc. | Selective estrogen receptor modulators with short half-lives and uses thereof |
EP2901821B1 (en) | 2012-09-28 | 2020-07-08 | Mevion Medical Systems, Inc. | Magnetic field regenerator |
US8927950B2 (en) | 2012-09-28 | 2015-01-06 | Mevion Medical Systems, Inc. | Focusing a particle beam |
EP2901820B1 (en) | 2012-09-28 | 2021-02-17 | Mevion Medical Systems, Inc. | Focusing a particle beam using magnetic field flutter |
CN104813750B (zh) | 2012-09-28 | 2018-01-12 | 梅维昂医疗系统股份有限公司 | 调整主线圈位置的磁垫片 |
EP2900324A1 (en) | 2012-09-28 | 2015-08-05 | Mevion Medical Systems, Inc. | Control system for a particle accelerator |
WO2014052709A2 (en) | 2012-09-28 | 2014-04-03 | Mevion Medical Systems, Inc. | Controlling intensity of a particle beam |
WO2014052734A1 (en) | 2012-09-28 | 2014-04-03 | Mevion Medical Systems, Inc. | Controlling particle therapy |
US10254739B2 (en) | 2012-09-28 | 2019-04-09 | Mevion Medical Systems, Inc. | Coil positioning system |
EP3342462B1 (en) | 2012-09-28 | 2019-05-01 | Mevion Medical Systems, Inc. | Adjusting energy of a particle beam |
SI2958907T1 (en) | 2013-02-19 | 2018-05-31 | Novartis Ag | Benzothiophene derivatives and their compositions as selective estrogen receptor antagonists |
US8791656B1 (en) | 2013-05-31 | 2014-07-29 | Mevion Medical Systems, Inc. | Active return system |
US9730308B2 (en) | 2013-06-12 | 2017-08-08 | Mevion Medical Systems, Inc. | Particle accelerator that produces charged particles having variable energies |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
WO2015048468A1 (en) | 2013-09-27 | 2015-04-02 | Mevion Medical Systems, Inc. | Particle beam scanning |
US10675487B2 (en) | 2013-12-20 | 2020-06-09 | Mevion Medical Systems, Inc. | Energy degrader enabling high-speed energy switching |
US9962560B2 (en) | 2013-12-20 | 2018-05-08 | Mevion Medical Systems, Inc. | Collimator and energy degrader |
US9661736B2 (en) | 2014-02-20 | 2017-05-23 | Mevion Medical Systems, Inc. | Scanning system for a particle therapy system |
US9950194B2 (en) | 2014-09-09 | 2018-04-24 | Mevion Medical Systems, Inc. | Patient positioning system |
US10786689B2 (en) | 2015-11-10 | 2020-09-29 | Mevion Medical Systems, Inc. | Adaptive aperture |
EP3481503B1 (en) | 2016-07-08 | 2021-04-21 | Mevion Medical Systems, Inc. | Treatment planning |
US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
HRP20231537T1 (hr) | 2016-12-01 | 2024-03-15 | Arvinas Operations, Inc. | Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora |
US10604506B2 (en) | 2017-01-26 | 2020-03-31 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
US11103730B2 (en) | 2017-02-23 | 2021-08-31 | Mevion Medical Systems, Inc. | Automated treatment in particle therapy |
CN111093767B (zh) | 2017-06-30 | 2022-08-23 | 美国迈胜医疗系统有限公司 | 使用线性电动机而被控制的可配置准直仪 |
WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
CN108299405A (zh) * | 2018-02-12 | 2018-07-20 | 李化绪 | 3-对n,n二乙基氨基苯基亚氨基类化合物及其在高脂血症药物中的应用 |
RU2020130837A (ru) | 2018-02-21 | 2022-03-21 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Комбинационная терапия апилимодом и глутаматергическими агентами |
CN113365641A (zh) * | 2018-09-12 | 2021-09-07 | 路易斯安那泽维尔大学 | 雌激素受体靶向拮抗剂 |
TW202041245A (zh) | 2019-03-08 | 2020-11-16 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之準直儀及降能器 |
PE20221582A1 (es) | 2019-12-19 | 2022-10-06 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2949470A (en) * | 1956-03-27 | 1960-08-16 | Endo Lab | Pyrrolidino-2, 6-dimethylacetanilide |
NL269099A (ru) * | 1960-09-09 | |||
US3862232A (en) * | 1963-07-03 | 1975-01-21 | Upjohn Co | 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof |
US3293263A (en) * | 1963-12-09 | 1966-12-20 | Upjohn Co | Diphenylbenzocycloalkenes |
US3320271A (en) * | 1964-06-01 | 1967-05-16 | Upjohn Co | 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes |
DE1300575B (de) * | 1965-05-21 | 1969-08-07 | Bristol Myers Co | Benzo[b]thiophene |
US3394125A (en) * | 1965-10-23 | 1968-07-23 | Bristol Myers Co | 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
US4117128A (en) * | 1976-08-03 | 1978-09-26 | Smithkline Corporation | Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity |
US4137414A (en) * | 1977-09-26 | 1979-01-30 | G. D. Searle & Co. | 5-Substituted-2-phenylbenzo[b]thiophene-3-alkylamines and related compounds |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
GB8311678D0 (en) * | 1983-04-28 | 1983-06-02 | Ici Plc | Phenol derivatives |
GB8705174D0 (en) * | 1987-03-05 | 1987-04-08 | Ici Plc | Heterocyclic compounds |
US5013761A (en) * | 1988-06-03 | 1991-05-07 | Eli Lilly And Company | Serotonin antagonists |
FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
US5254568A (en) * | 1990-08-09 | 1993-10-19 | Council Of Scientific & Industrial Research | Benzopyrans as antiestrogenic agents |
DE4117512A1 (de) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
WO1993010742A2 (en) * | 1991-11-27 | 1993-06-10 | Novo Nordisk A/S | Chemical compounds, their preparation and use |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
US5384332A (en) * | 1994-05-11 | 1995-01-24 | Eli Lilly And Company | Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives |
US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
-
1995
- 1995-02-28 US US08/396,401 patent/US5510357A/en not_active Expired - Lifetime
- 1995-06-06 US US08/470,536 patent/US5510498A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,506 patent/US5510358A/en not_active Expired - Lifetime
- 1995-06-06 US US08/469,952 patent/US5492922A/en not_active Expired - Lifetime
- 1995-06-06 US US08/469,983 patent/US5488058A/en not_active Expired - Lifetime
- 1995-11-03 US US08/552,636 patent/US5723474A/en not_active Expired - Lifetime
-
1996
- 1996-02-26 HU HU9600448A patent/HUP9600448A3/hu unknown
- 1996-02-27 AR ARP960101538A patent/AR027162A1/es active IP Right Grant
- 1996-02-27 RU RU96103683/04A patent/RU2158737C2/ru not_active IP Right Cessation
- 1996-02-27 ZA ZA9601563A patent/ZA961563B/xx unknown
-
2007
- 2007-04-03 GE GEAP20079959A patent/GEP20084496B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR027162A1 (es) | 2003-03-19 |
US5488058A (en) | 1996-01-30 |
US5723474A (en) | 1998-03-03 |
US5510357A (en) | 1996-04-23 |
HUP9600448A3 (en) | 2000-04-28 |
HU9600448D0 (en) | 1996-04-29 |
GEP20084496B (en) | 2008-09-25 |
HUP9600448A2 (hu) | 1998-09-28 |
RU2158737C2 (ru) | 2000-11-10 |
US5510358A (en) | 1996-04-23 |
US5510498A (en) | 1996-04-23 |
US5492922A (en) | 1996-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA961563B (en) | Benzothiophene compounds, intermediates, compositions, and methods. | |
HK1013991A1 (en) | Benzothiophene compounds, intermediates, compositions, and methods | |
ZA961291B (en) | Naphthyl compounds, intermediates, compositions, and methods. | |
AU3686495A (en) | Benzothiophene compounds, compositions, and methods | |
ZA9711092B (en) | Novel compounds. | |
ZA9610858B (en) | Heteroclyclic compounds. | |
ZA964473B (en) | Endoparasiticidal compositions. | |
ZA975261B (en) | Composition. | |
ZA965505B (en) | Novel compounds. | |
ZA973629B (en) | Pesticidal composition. | |
DE69610844D1 (en) | Hydroformylierungsverfahren. | |
ZA97559B (en) | Dihalopropene compounds, their use and intermediates for their production. | |
ZA9811502B (en) | Novel composition. | |
PL326837A1 (en) | 25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles | |
ZA97928B (en) | Novel heteroaryl-oxazolidinones. | |
ZA964560B (en) | Anit-viral compounds. | |
ZA965292B (en) | Enzymatic composition. | |
PL334473A1 (en) | Substituted 2-benzoylcyclohexano-1,3-diones | |
ZA974052B (en) | New benzothiazolinones. | |
GB9615378D0 (en) | Benzene compounds, intermediates, processes, compositions, and methods | |
ZA974056B (en) | New thiazolopyridines. | |
ZA9610458B (en) | Novel method. | |
ZA971775B (en) | Novel method. | |
ZA981739B (en) | Composition. | |
AU699753C (en) | Benzothiophene compounds, intermediates, compositions and methods |